A Phase 3 interventional study of Vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Active, not recruiting at 20 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 28th largest by enrollment, is one of 5 that started in 2021, is one of 14 in phase 3, and was the 26th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 35th largest by enrollment of the 43 interventional ones that give a count, is one of 9 that started in 2021, is one of 21 in phase 3, and was the 46th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD). Vedolizumab is commercially available in Japan for 8-weekly treatment but not for 4-weekly treatment.
The study doctors will also monitor side effects from the study treatment.
This study will take place in Japan.
At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will receive vedolizumab intravenously once every 4 weeks. After 3 infusions of vedolizumab (which will be 12 weeks of treatment), the study doctor will assess if symptoms of the participants have improved.
Participants who do not have improved symptoms after 12 weeks of treatment with vedolizumab will stop this treatment. Then, they will visit the study clinic 16 weeks after their last infusion of vedolizumab for a final check-up.
Participants who have improved symptoms after 12 weeks of treatment with vedolizumab will continue to receive vedolizumab every 4 weeks. Then, after their last infusion of vedolizumab, the participants will visit the study clinic 16 weeks later for a final check-up. Finally, the study clinic will make a phone call to each participant 6 months after their last infusion to check if they have any health problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
UC cohort
The participant has moderate to severe UC, who had previously shown clinical response in initial treatment with commercially available vedolizumab IV, then experienced secondary loss of response during maintenance therapy with commercially available vedolizumab IV Q8W.
Previous "clinical response" is to be judged by the investigators referring to one of the following criteria.
"Secondary loss of response" is to be judged by the investigators referring to one of the following criteria.
CD cohort
The participant has moderate to severe CD, who had previously shown clinical response in initial treatment with commercially available vedolizumab IV, then experienced secondary loss of response during maintenance therapy with commercially available vedolizumab IV Q8W.
Previous "clinical response" is to be judged by the investigators referring to one of the following criteria.
"Secondary loss of response" is to be judged by the investigators referring to one of the following criteria.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
Drug: Vedolizumab
Vedolizumab 300 mg, IV infusion, for up to 12 weeks Q4W for Treatment phase, and until the date of marketing approval of vedolizumab IV Q4W or study termination for Extension phase.
Drug: Vedolizumab
Vedolizumab 300 mg, IV infusion
UC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score
Clinical response was defined as a reduction of greater than or equal to (\>=) 2 points and \>=25 percent (%) in modified mayo score, and a decrease of \>=1 point in rectal bleeding sub-score or rectal bleeding sub-score of less than or equal to (\<=) 1 from baseline (Week 0). Mayo score was an instrument designed to measure disease activity of UC. Modified mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score range of 0 to 9. Here, a higher score indicated more severe disease.
Time frame: At Week 12
CD Cohort: Percentage of Participants With Clinical Response at Week 12
Clinical response was defined as a reduction of \>=70 points in Crohn's Disease Activity Index (CDAI) score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicated greater disease activity.
Time frame: At Week 12
UC Cohort: Percentage of Participants With Clinical Remission at Week 12 Based on Modified Mayo Score
Clinical remission was defined as a modified Mayo score of less than or equal to (\<=) 2, and no individual sub-score greater than (\>) 1. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and Mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 9. Here, a higher score indicated a more severe disease.
Time frame: At Week 12
UC Cohort: Percentage of Participants With Mucosal Healing at Week 12
Mucosal healing was defined as a Mayo endoscopic sub-score of \<=1, in participants with baseline Mayo endoscopic sub-score of \>=2. Mayo score consisted of 4 sub-scores: stool frequency, rectal bleeding, mayo endoscopic sub-score (findings on endoscopy) and physician's global assessment, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 12. Here, a higher score indicated a more severe disease.
Time frame: At Week 12
UC Cohort: Percentage of Participants With Corticosteroid-Free Remission Based on Partial Mayo Score
Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and were in clinical remission based on partial Mayo score at Week 52. Clinical remission based on partial Mayo score was defined as a partial Mayo score of =\<2, and no individual sub-score \>1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consists of 3 sub-scores: stool frequency, rectal bleeding, and physician's global assessment, each graded from 0 to 3 with higher scores indicated more severe disease. These scores are summed to give a total score range of 0 to 9. Here, higher scores indicated more severe disease.
Time frame: At Week 52
CD Cohort: Percentage of Participants With Clinical Remission at Week 12
Clinical remission was defined as a CDAI score of \<=150. A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: At Week 12
CD Cohort: Percentage of Participants With Enhanced Clinical Response at Week 12
Enhanced clinical response was defined as a reduction of \>=100 points in CDAI score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: At Week 12
CD Cohort: Percentage of Participants With Corticosteroid-Free Remission
Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52.
Time frame: At Week 52
Participants took part in the study at 20 investigative sites in Japan from 04 June 2021.
| Milestone | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg |
|---|---|---|
| Started | 41 | 15 |
| Completed | 0 | 0 |
| Not completed | 41 | 15 |
| Withdrew: Ongoing in the study | 41 | 15 |
Clinical response was defined as a reduction of greater than or equal to (\>=) 2 points and \>=25 percent (%) in modified mayo score, and a decrease of \>=1 point in rectal bleeding sub-score or rectal bleeding sub-score of less than or equal to (\<=) 1 from baseline (Week 0). Mayo score was an instrument designed to measure disease activity of UC. Modified mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score range of 0 to 9. Here, a higher score indicated more severe disease.
| percentage of participants | UC Cohort: Vedolizumab 300 mg |
|---|---|
| UC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score | 41.5 (26.3 to 57.9) |
Clinical response was defined as a reduction of \>=70 points in Crohn's Disease Activity Index (CDAI) score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicated greater disease activity.
| percentage of participants | CD Cohort: Vedolizumab 300 mg |
|---|---|
| CD Cohort: Percentage of Participants With Clinical Response at Week 12 | 86.7 (59.5 to 98.3) |
Clinical remission was defined as a modified Mayo score of less than or equal to (\<=) 2, and no individual sub-score greater than (\>) 1. Mayo score was an instrument designed to measure disease activity of UC. Modified Mayo score consisted of 3 sub-scores: stool frequency, rectal bleeding, and Mayo endoscopic sub-score (findings on endoscopy), each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 9. Here, a higher score indicated a more severe disease.
| percentage of participants | UC Cohort: Vedolizumab 300 mg |
|---|---|
| UC Cohort: Percentage of Participants With Clinical Remission at Week 12 Based on Modified Mayo Score | 0 (0.0 to 8.6) |
Mucosal healing was defined as a Mayo endoscopic sub-score of \<=1, in participants with baseline Mayo endoscopic sub-score of \>=2. Mayo score consisted of 4 sub-scores: stool frequency, rectal bleeding, mayo endoscopic sub-score (findings on endoscopy) and physician's global assessment, each graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed to give a total score ranged of 0 to 12. Here, a higher score indicated a more severe disease.
| percentage of participants | UC Cohort: Vedolizumab 300 mg |
|---|---|
| UC Cohort: Percentage of Participants With Mucosal Healing at Week 12 | 0 (0.0 to 8.6) |
Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and were in clinical remission based on partial Mayo score at Week 52. Clinical remission based on partial Mayo score was defined as a partial Mayo score of =\<2, and no individual sub-score \>1. Mayo score was an instrument designed to measure disease activity of UC. Partial Mayo score consists of 3 sub-scores: stool frequency, rectal bleeding, and physician's global assessment, each graded from 0 to 3 with higher scores indicated more severe disease. These scores are summed to give a total score range of 0 to 9. Here, higher scores indicated more severe disease.
| percentage of participants | UC Cohort: Vedolizumab 300 mg |
|---|---|
| UC Cohort: Percentage of Participants With Corticosteroid-Free Remission Based on Partial Mayo Score | 0 (0.0 to 84.2) |
Clinical remission was defined as a CDAI score of \<=150. A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | CD Cohort: Vedolizumab 300 mg |
|---|---|
| CD Cohort: Percentage of Participants With Clinical Remission at Week 12 | 46.7 (21.3 to 73.4) |
Enhanced clinical response was defined as a reduction of \>=100 points in CDAI score from baseline (Week 0). A CDAI was a multi-item instrument that measured severity of active Crohn's Disease monitored over 7 days included participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI total score was equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores ranged approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | CD Cohort: Vedolizumab 300 mg |
|---|---|
| CD Cohort: Percentage of Participants With Enhanced Clinical Response at Week 12 | 80.0 (51.9 to 95.7) |
Corticosteroid-free remission was defined as participants using oral corticosteroids at baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52.
| percentage of participants | CD Cohort: Vedolizumab 300 mg |
|---|---|
| CD Cohort: Percentage of Participants With Corticosteroid-Free Remission | 0 (0.0 to 84.2) |
Collected over From study start date to primary completion date (up to 3.99 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UC Cohort: Vedolizumab 300 mg | 0/41 (0%) | 3/41 (7.3%) | 19/41 (46.3%) |
| CD Cohort: Vedolizumab 300 mg | 0/15 (0%) | 6/15 (40%) | 14/15 (93.3%) |
| Event | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg |
|---|---|---|
| COVID-19Infections and infestations | 0/41 | 1/15 |
| Crohn's diseaseGastrointestinal disorders | 0/41 | 1/15 |
| GastroenteritisInfections and infestations | 0/41 | 1/15 |
| IleusGastrointestinal disorders | 0/41 | 1/15 |
| Liver abscessInfections and infestations | 0/41 | 1/15 |
| SepsisInfections and infestations | 0/41 | 1/15 |
| Abdominal painGastrointestinal disorders | 1/41 | 0/15 |
| Colitis ulcerativeGastrointestinal disorders | 1/41 | 0/15 |
| UreterolithiasisRenal and urinary disorders | 1/41 | 0/15 |
| Event | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 8/41 | 5/15 |
| Aphthous ulcerGastrointestinal disorders | 0/41 | 2/15 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/41 | 2/15 |
| Crohn's diseaseGastrointestinal disorders | 0/41 | 2/15 |
| Colitis ulcerativeGastrointestinal disorders | 3/41 | 0/15 |
| AnaemiaBlood and lymphatic system disorders | 1/41 | 1/15 |
| COVID-19Infections and infestations | 2/41 | 1/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/41 | 1/15 |
| DepressionPsychiatric disorders | 0/41 | 1/15 |
| DizzinessNervous system disorders | 1/41 | 1/15 |
The full analysis set (FAS) included all participants who received at least 1 dose of study drug. UC cohort and CD cohort were analyzed separately. Numbers in the total column are simply data from the two cohorts combined and not part of the results produced within the study.
| Age, Continuous(years) | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 49.5 ± 16.93 | 41.5 ± 12.84 | 47.4 ± 16.22 |
| Sex: Female, Male(Participants) | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Female | 15 | 7 | 22 |
| Male | 26 | 8 | 34 |
| Ethnicity (NIH/OMB)(Participants) | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 41 | 15 | 56 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | UC Cohort: Vedolizumab 300 mg | CD Cohort: Vedolizumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 41 | 15 | 56 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2021 to primary completion in May 2025, 47 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 47 months is close to that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab